Xifeng Wu, M.D., Ph.D.
Director, Center for Public Health and Translational Genomics
Professor, Department of Epidemiology
Dr. Xifeng Wu is a Professor of the Department of Epidemiology, Director of the Center of Translational and Public Health Genomics, and Leader of the Premalignant Genome Atlas Program at The University of Texas MD Anderson Cancer Center. She also holds the endowed Betty B. Marcus Chair in Cancer Prevention. She earned her medical degree from Fudan University in 1984, and following a fellowship at the National Laboratory of Industrial Environment and Risk Analysis (INERIS) in France, she came to the US and earned her Ph.D. from The University of Texas School of Public Health in 1994.
Dr. Wu’s multifaceted molecular epidemiology program bridges the fields of epidemiology, laboratory, clinical, and computational research. The overall theme of her research program is to use highly innovative and integrative research strategies to discover novel modifiable risk factors, uncover molecular signatures and create robust prediction models for risk stratification across the cancer continuum. She has initiated large cancer case control studies on esophageal, bladder, renal, and colorectal cancer and clinical outcome studies on those cancers and lung cancer. She established MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC), the Premalignant Lesion Patient Cohort (PLPC), and the long-term survivorship cohort. Furthermore, she developed successful productive collaboration with MJ Health Research Foundation in Taiwan on a large prospective cohort of over half a million individuals.
Dr. Wu is a highly productive cancer epidemiologist with over 400 publications, many in highly acclaimed journals. She consistently maintains a high level of funding from the NCI, holds a CPRIT grant, is co-Director of or leads projects on multiple SPOREs, and is contributing to a number of our moonshot programs.
Dr. Wu has received many awards, including MD Anderson’s Faculty Scholar Award, The University of Texas Ashbel Smith Professorship, the Margaret and James A. Elkins Jr. Faculty Achievement Award in Cancer Prevention, the Julie and Ben Rogers Award for Excellence in Research, the Robert M. Chamberlain Distinguished Mentor Award, Houston’s 50 most influential women of 2014, and Leading Mentor in Cancer Prevention in 2010 and 2016. Her trainees received over 57 awards and recognitions inside the Institution and nationwide. She currently serves on study sections for the US National Cancer Institute, the European Research Council, the Cancer Research United Kingdom, and several others.
Maria Alma Rodriguez, M.D.
Co-Director, Center for Public Health and Translational Genomics
Vice President of Medical Affairs, Office of the EVP, Physician-in-Chief
Dr. Maria Alma Rodriguez, received her medical degree from the University of Texas Medical School at Houston and did her residency in Internal Medicine at the UT Health Sciences Center in San Antonio, Texas. She trained as a cancer specialist at the University of Arizona Cancer Center in Tucson, Arizona. She has been a clinician and clinical investigator at UT MD Anderson Cancer Center (MDACC) since 1986. Her expertise is in the treatment of patients with lymphomas. She has published articles, authored book chapters, and co-edited a book on the treatment of lymphomas. She completed a Fellowship of the National Association of Public Hospitals in 2006, and was named Fellow in Clinical Safety & Effectiveness at MDACC in 2007.
Dr. Rodriguez has served on numerous committees within the MDACC institution, including the Institutional Review Board (IRB) and Clinical Ethics Committee, and nationally on the Oncology Drugs Advisory Committee for the U.S. Food and Drug Administration, and the Ethics Committee of the American Society of Clinical Oncology. Currently, she serves on the Steering Committee of the National Comprehensive Cancer Network Lymphoma Database, and is Vice President of Medical Affairs at MDACC.
Dr. Rodriguez is Chair of the Cancer Survivorship Steering Committee. She has been leading the rapid evolvement of the Cancer Survivorship initiative at MDACC for the past two years. Dr. Rodriguez was recently appointed to the American Society of Clinical Oncology’s Survivorship Committee.